α-Mangostin extracted from the pericarp of the mangosteen (Garcinia mangostana Linn) reduces tumor growth and lymph node metastasis in an immunocompetent xenograft model of metastatic mammary cancer carrying a p53 mutation by Shibata, Masa-Aki et al.
RESEARCH ARTICLE Open Access
a-Mangostin extracted from the pericarp of the
mangosteen (Garcinia mangostana Linn) reduces
tumor growth and lymph node metastasis in an
immunocompetent xenograft model of metastatic
mammary cancer carrying a p53 mutation
Masa-Aki Shibata
1,2*, Munekazu Iinuma
3, Junji Morimoto
4, Hitomi Kurose
2, Kanako Akamatsu
5, Yasushi Okuno
5,
Yukihiro Akao
6 and Yoshinori Otsuki
2
Abstract
Background: The mangosteen fruit has a long history of medicinal use in Chinese and Ayurvedic medicine.
Recently, the compound a-mangostin, which is isolated from the pericarp of the fruit, was shown to induce cell
death in various types of cancer cells in in vitro studies. This led us to investigate the antitumor growth and
antimetastatic activities of a-mangostin in an immunocompetent xenograft model of mouse metastatic mammary
cancer having a p53 mutation that induces a metastatic spectrum similar to that seen in human breast cancers.
Methods: Mammary tumors, induced by inoculation of BALB/c mice syngeneic with metastatic BJMC3879luc2 cells, were
subsequently treated with a-mangostin at 0, 10 and 20 mg/kg/day using mini-osmotic pumps and histopathologically
examined. To investigate the mechanisms of antitumor ability by a-mangostin, in vitro studies were also conducted.
Results: Not only were in vivo survival rates significantly higher in the 20 mg/kg/day a-mangostin group versus
controls, but both tumor volume and the multiplicity of lymph node metastases were significantly suppressed.
Apoptotic levels were significantly increased in the mammary tumors of mice receiving 20 mg/kg/day and were
associated with increased expression of active caspase-3 and -9. Other significant effects noted at this dose level
were decreased microvessel density and lower numbers of dilated lymphatic vessels containing intraluminal tumor
cells in mammary carcinoma tissues.
In vitro, a-mangostin induced mitochondria-mediated apoptosis and G1-phase arrest and S-phase suppression in the
cell cycle. Since activation by Akt phosphorylation plays a central role in a variety of oncogenic processes, including cell
proliferation, anti-apoptotic cell death, angiogenesis and metastasis, we also investigated alterations in Akt
phosphorylation induced by a-mangostin treatment both in vitro and in vivo. Quantitative analysis and
immunohistochemistry showed that a-mangostin significantly decreased the levels of phospho-Akt-threonine 308
(Thr308), but not serine 473 (Ser473), in both mammary carcinoma cell cultures and mammary carcinoma tissues in vivo.
Conclusions: Since lymph node involvement is the most important prognostic factor in breast cancer patients, the
antimetastatic activity of a-mangostin as detected in mammary cancers carrying a p53 mutation in the present
study may have specific clinical applications. In addition, a-mangostin may have chemopreventive benefits and/or
prove useful as an adjuvant therapy, or as a complementary alternative medicine in the treatment of breast cancer.
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Breast cancer represents a major health problem in
women, with more than 1,000,000 new cases and
370,000 deaths yearly worldwide [1]. Perhaps more wor-
risome is an apparently increasing incidence of breast
cancer among younger women under 40 years of age
recently reported in many countries worldwide [2-4].
The lethality of breast cancer is largely due to metasta-
sis, preferentially to the lymph nodes, lungs and bones
[5]; in order to delay the progression of breast cancer
and prolong patient life, more effective chemopreventive
and antimetastatic treatments and less toxic chemother-
apeutic agents are desperately required.
The mangosteen (Garcinia mangostana Linn) has been
dubbed the ‘queen of fruit’ in its native Thailand. Man-
gosteens are small (about 4 to 8 cm in diameter) round
fruits with a thick, brittle, deep purple spherical outer
shell or pericarp. The edible snow white endocarp of the
mangosteen is arranged in a circle of wedge-shaped, 4- to
8-segmented arils (Figure 1A). The fruit has a long his-
tory of medicinal use in both Chinese and Ayurvedic
medicine. For centuries, people in Southeast Asia have
used dried mangosteen pericarp for medicinal purposes;
it is used as an antiseptic, an anti-inflammatory, an anti-
parasitic, an antipyretic, an analgesic, and as a treatment
for skin rashes [6].
The compound a-mangostin, which was isolated
from the pericarp, has recently been shown to induce
cell-cycle arrest and apoptosis in various types of
human cancer cells [7-10]. a-Mangostin has addition-
ally been shown to inhibit cell invasion and migration
in mammary and prostate cancer cells and is asso-
ciated with down-regulation of MMP-2 and MMP-9
[11,12]. In one in vivo animal cancer model, crude
a-mangostin (comprised of 78% a-mangostin and 16%
g-mangostin) administered in the diet significantly sup-
pressed formation of aberrant crypt foci, considered to
be a putative preneoplastic lesion, in rat colon carcino-
genesis [13]. Furthermore, we have more recently
reported that dietary administration of panaxanthone,
a compound of approximately 75% to 85% a-mangos-
tin and 5% to 15% g-mangostin with the sum of both
contents > 90%, significantly inhibited both tumor
growth and metastasis in a mouse model of mammary
cancer [14].
Here, we investigated the antitumor potential of puri-
fied a-mangostin, focusing on its antimetastatic ability,
in a mouse metastatic mammary cancer model carrying
a p53 mutation that demonstrates a metastatic spectrum
similar to that seen in human breast cancers [15-17]. In
addition, we analyzed the effect of a-mangostin expo-
sure on apoptosis, DNA synthesis, and cell cycle arrest
in vitro using metastatic mouse mammary carcinoma
cells. Since Akt phosphorylation has been shown to par-
ticipate in cell growth, survival, proliferation, motility,
and/or invasion in various cancers, including human
breast cancer, we further examined the influence of a-
mangostin treatment on Akt phosphorylation both in
vitro and in vivo.
Methods
Experimental regimen
Mangosteen (Garcinia mangostana Linn) pericarps (Fig-
ure 1A) collected in Thailand were dried, ground, and
successively extracted in water and 50% ethanol. After
freeze-drying the 50% ethanol extract, the resultant
dried powder was suspended in water partitioned with
ethyl acetate. The ethyl acetate extract was then purified
by chromatography on silica gel with the n-hexane-ethyl
acetate system and recrystallized to give a-mangostin at
> 98% purity. The chemical structure of a-mangostin is
shown in Figure 1B. For in vitro use, crystallized a-man-
gostin was dissolved in dimethyl sulphoxide (DMSO),
and aliquots of stock 20 mM solution were stored at
-20°C.
MeO 
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Figure 1 Gross appearance of a-mangostin and its chemical
structure. (A) Gross appearance of mangosteen fruit. The edible
endocarp of the mangosteen is snow white and botanically defined
as an aril. The circle of wedge-shaped arils contains four to eight
segments. (B) The chemical structure of a-mangostin; molecular
formula, C24H26O6; molecular weight, 410.
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The murine BJMC3879 mammary adenocarcinoma cell
line was derived from a metastatic focus within a lymph
node of an inoculated BALB/c mouse in an earlier
study; the cell line continues to show a high metastatic
propensity, especially to lymph nodes and lungs [18-20],
a trait retained through culture. The BJMC3879luc2
mammary carcinoma cell line used in our investigations
was generated by stable transfection of the luc2 gene
(an improved firefly luciferase gene) into the parent
BJMC3879 cell line [21]. BJMC3879luc2 cells were
maintained in RPMI-1640 medium containing 10% fetal
bovine serum with streptomycin/penicillin at 37°C
under 5% CO2. MDA-MB231, a human mammary carci-
noma cell line stably expressing the green fluorescence
protein (GFP)[22] was maintained in DMEM or RPMI-
1640 medium containing 10% fetal bovine serum. Most
of the in vitro analyses of caspase, cytochrome c release,
Bid and cell cycle were conducted using the mouse
BJMC3879luc2 cells, but Akt-phosphorylation analysis
was performed in both human MDA-MB231 cells in
vitro and mouse BJMC3879luc2 cells in vivo.
Thirty six-week-old female BALB/c mice were used in
this study (Japan SLC, Hamamatsu, Japan). The animals
were housed five per plastic cage on wood chip bedding
with free access to water and food under controlled
temperature (21 ± 2°C), humidity (50 ± 10%), and light-
ing (12-12 hours light-dark cycle) conditions. All ani-
mals were held for a one-week acclimatization period
before study commencement. This animal experiment
was approved by the Animal Experiment Committee of
Osaka Medical College. Mice were treated in accordance
with the procedures outlined in the Guide for the Care
and Use of Laboratory Animals at Osaka Medical Col-
lege, the Japanese Government Animal Protection and
Management Law (No.105) and the Japanese Govern-
ment Notification on Feeding and Safekeeping of Ani-
mals (No.6).
Cell viability
BJMC3879luc2 and MDA-MB231 cells were grown in
RPMI-1640 medium supplemented with 10% (v/v) heat-
inactivated fetal bovine serum and 2 mM L-glutamine
under an atmosphere of 95% air and 5% CO2 at 37°C.
These cells were plated into 96-well plates (1 × 10
4
cells/well) one day before a-mangostin treatment. They
were subsequently incubated for 24 hours with culture
medium containing DMSO vehicle alone or with med-
ium containing a-mangostin at various concentrations
up to 20 μM. Cell viability was determined using a Cell-
Titer-Bule Cell Viability Assay (Promega Co., Madison,
WI, USA). The IC50 for each cell line under these con-
ditions was found to be 12 μM a-mangostin in
BJMC3879luc2 and 20 μM in MDA-MB231 cells; thus,
all in vitro studies were performed using exposure to
these respective concentrations of a-mangostin for
24 hours.
Caspase activity and TUNEL assay
BJMC3879luc2 cells were grown in two-well chambered
slides and treated with 12 μM a-mangostin for 24
hours. The cells were then fixed in 4% formaldehyde
solution in phosphate buffer and terminal deoxynucleo-
tidyl transferase-mediated dUTP-FITC nick end-labeling
(TUNEL) staining was performed according to the man-
ufacturer’s protocol (Wako Pure Chemical Industries,
Osaka, Japan).
BJMC3879luc2 cells were plated into 96-well plates at
a concentration of 1 × 10
4 cells/well one day before
a-mangostin treatment. Cells were treated with 12 μM
a-mangostin or DMSO alone for 48 or 72 hours; subse-
quent cell viability was measured using a CellTiter-Blue
Cell Viability Assay (Promega). The activities of caspase-
8, caspase-9 and caspase-3 were measured using a lumi-
nescent assay kit (Promega). Caspase activity was mea-
sured in terms of the luminescent signal produced by
caspase cleavage of the corresponding substrate using a
Luminoskan Ascent kit (Thermo Electron Co., Helsinki,
Finland). Caspase activity levels were then adjusted to
account for the corresponding cell viability data as pre-
viously reported [16].
Release of cytochrome c
After incubation with either DMSO alone or with
12 μM a-mangostin for 24 hours, both floating and
attached BJMC3879luc2 cells were harvested, rinsed
once in PBS, re-suspended in cell lysis buffer, incubated
for one hour at room temperature, and centrifuged at
1000 × g for 15 minutes. The resultant supernatant was
diluted at least five-fold. Supernatants containing the
cytosolic fraction were collected separately and the pro-
tein concentrations were determined. To evaluate cyto-
chrome c release into the cytosol, cytochrome c was
measured using a Cytochrome c ELISA kit (R&D Sys-
tems, Inc, Minneapolis, MN, USA).
Caspase inhibitor experiment
BJMC3879luc2 cells were treated for 24 hours with
either 10 μM or 100 μM of the following caspase inhibi-
tors: z (N-benzyloxycarbonyl)-VAD-fmk (fluoromethyl
ketone) against broad-spectrum caspases; Ac (acetyl)-
DNLD-CHO (aldehyde) against caspase-3; z-IETD-fmk
against caspase-8; and z-LEHD-fmk against caspase-9.
With the exception of the caspase-3 inhibitor, which
was purchased from Peptide Institute, Inc., Osaka,
Japan, these caspase inhibitors were purchased from
MBL, Inc. Nagoya, Japan. Although DEVD has generally
been used as a caspase-3 inhibitor, it has recently been
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present experiment, we therefore decided to use
Ac-DNLD-CHO to inhibit caspase-3. Two hours after
inhibitor treatments, cells were exposed to 12 μM
a-mangostin and cell viability was measured 24 hours
later using a fluorescent assay kit (CellTiter-Blue Cell
Viability Assay, Promega).
Cell-cycle distribution
Flow cytometric analysis was conducted on trypsinized
BJMC3879luc2 cell suspensions that were harvested after
24 hours exposure to 12 μM a-mangostin and fixed in
cold 70% ethanol. The cells were stained with a 50 μg/ml
propidium iodide solution containing 100 μg/ml RNase
A for 30 minutes at 37°C and then placed on ice just
prior to flow cytometric analysis (EPICS Elite ESP; Coul-
ter Co., Miami, FL, USA). The percentage of cells in each
phase of the cell cycle was determined using a Multicycle
Cell Cycle Analysis program (Coulter).
Western blotting
Total protein was extracted from whole cell lysates of
BJMC3879luc2 cells and MDA-MB231 cells treated with
DMSO (control) or a-mangostin according to the IC50
data previously stated. Total protein (40 μg) was fractio-
nated on 14% Tris-glycine gels under reducing condi-
tions and transferred to nitrocellulose membranes. The
membranes were incubated with primary antibodies for
the following proteins: Bid, total Akt, phospho-Akt-
Thr308, phospho-Akt-Ser473, and b-actin. Membranes
were then incubated with the corresponding secondary
antibodies conjugated with horseradish peroxidase
(HRP). All antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA), with the excep-
tion of the antibodies for Bid (R&D Systems) and phos-
pho-Akt-Ser473 (Cell Signaling Technology, Danvers,
MA, USA). Antibody binding was subsequently visua-
lized by exposure to an enhancing chemiluminescence
reagent (Amersham ECL; GE Healthcare UK Ltd., Buck-
inghamshire, UK). Blots were visualized using a LAS-
3000 image analyzer (Fujifilm, Co., Tokyo, Japan).
Measurement of Akt phosphorylation
MDA-MB231 cells were treated with 20 μM a-mangos-
tin or DMSO (vehicle control) for up to six hours. Pro-
tein was extracted using cell lysis buffer containing
protease and phosphatase inhibitor cocktail. Total Akt,
Akt phosphorylated-threonine 308 (phospho-Akt-
Thr308) and Akt phosphorylated-serine 473 (phospho-
Akt-Ser473) were measured with phosphorylation assay
kits (AlphaScreen SureFire for Akt signaling and
GAPDH, Perkin Elmer, Waltham, MA, USA) using a
multilabel plate reader (model EnSpire™ Alpha, Perkin
Elmer). Data were corrected against glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) values and
expressed as mean ± SD.
In vivo study of a-mangostin in a metastatic mammary
cancer model
Two dosages of a-mangostin - 10 and 20 mg/kg/day -
were selected for the in vivo studies in mice based on
the results of preliminary investigations. In brief, no dif-
ferences in body or organ weights were found in mice
on a four-week toxicity study of crude a-mangostin
administered 0, 4, 20, 40 and 120 mg/kg by gavage. The
study demonstrated that mice treated with more than
20 mg/kg/day showed significant increases in NK activ-
ity [25]; therefore, since 20 mg/kg/day appears to be the
highest concentration that shows no harmful effect, we
chose 20 mg/kg as the dose to use in the present study.
It was difficult and expensive to obtain large amounts
of the pure a-mangostin. Rather than subject the mice
to the stress of daily gavage as well as to minimize
unwanted loss of an invaluable test agent, a-mangostin
was continuously administered via subcutaneously
implanted mini-osmotic pumps (Alzet model 2002, Dur-
ect Co., Cupertino, CA, USA) that were calibrated to
release 0.5 μl of solution per hour. a-Mangostin solu-
tions (15 mg/ml and 30 mg/ml) in a DMSO/100% etha-
nol (1:3, v/v) vehicle were prepared. Control mice
received the DMSO/100% ethanol vehicle alone. Since
the pumps were calibrated to release for 14 days, they
were replaced every other week.
BJMC3879luc2 cells, at a concentration of 2.5 × 10
6
cells/0.3 ml in phosphate-buffered saline, were subcuta-
neously inoculated into the right inguinal region of 30
female BALB/c mice. Three weeks later, when tumors
had reached approximately 0.4-0.6 cm in diameter, mice
were exposed to 0, 10 or 20 mg/kg/day a-mangostin via
the mini-osmotic pumps for six weeks. Individual body
weights were recorded weekly. Each mammary tumor
was also measured weekly using digital calipers, and
tumor volumes were calculated using the formula of
maximum diameter × (minimum diameter)
2 × 0.4 [26].
All surviving mice were euthanized with isoflurane
anesthesia after week six. One hour prior to euthanasia,
all animals were intraperitoneally injected with 50 mg/
kg 5-bromo-2’-deoxyuridine (BrdU, Sigma Co., St. Lois,
MO, USA) as a means to quantify the degree of tumor
malignancy through DNA synthesis.
Bioluminescence imaging in vivo
At week six, five mice from each group were anesthetized
by isoflurane inhalation administered via the SBH Scien-
tific anesthesia system (SBH Designs, Inc., Windsor,
Ontario, Canada). Each anesthetized mouse received an
intraperitoneal injection of 3 mg of D-luciferin potassium
salts (Wako Pure Chemical Industries). Bioluminescence
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France) was performed. The bioluminescent signals
received during the six minute acquisition time were
quantified using Photovision software (Biospace Lab).
Histopathological analyses
At necropsy following euthanasia at week six, the
tumors and lymph nodes were removed from each
mouse, fixed in 10% phosphate buffered formaldehyde
solution and processed through to paraffin embedding.
The lymph nodes from the axillary and femoral regions
were routinely removed, along with lymph nodes that
appeared abnormal. Other organs that appeared abnor-
mal were also excised and preserved in the fixative solu-
tion. Lungs were inflated with formaldehyde solution
prior to excision and immersion in fixative; the fixed
individual lobes were subsequently removed from the
bronchial tree and examined for metastatic foci and
similarly processed through to paraffin embedding. All
paraffin-embedded tissues were cut at 4 μm and sequen-
tial sections were either stained with hematoxylin and
eosin (H&E) for histopathological examination or left
unstained for immunohistochemical analysis.
p53 and phospho-Akt immunohistochemistry
The labeled streptavidin-biotin (LSAB) method (Dako
Co., Glostrup, Denmark) was used for p53 immunohis-
tochemistry. Unstained sections were immersed in dis-
tilled water and heated for antigen retrieval prior to
incubation with a p53 mouse monoclonal antibody
(Clone Pab240, Santa Cruz Biotechnology) that reacts to
the mutant protein in fixed specimens. Phosphorylated
Akt expression in tissues was evaluated using phospho-
Akt rabbit antibodies for Thr308 (Santa Cruz Biotech-
nology) and Ser473 (Cell Signaling Technology).
Apoptosis and active-caspases in mammary tumors
For quantitative analysis of cell death, sections from par-
affin-embedded tumors were assayed using the TUNEL
method in conjunction with an apoptosis in situ detec-
tion kit (Wako Pure Chemical Industries), with minor
modifications to the manufacturer’s protocol. TUNEL-
positive cells - regarded mainly as apoptotic cells - were
counted in viable regions peripheral to areas of necrosis
in tumor sections. The slides were scanned at low-
power (× 100) magnification to identify those areas hav-
ing the highest density of TUNEL-positive cells. Four
fields neighboring an area of high TUNEL positivity
were then selected and counted at higher (× 200-400)
magnification. The number of TUNEL-positive cells was
expressed as number per cm
2.
Active caspase expression in the mammary tumor tis-
sues was immunohistochemically detected using anti-
cleaved caspase-3 and anti-cleaved caspase-9 rabbit
polyclonal antibodies (Cell Signaling Technology).
Immunohistochemistry was conducted using the LSAB
method, and CSA II amplification (Dako) was addition-
ally applied to detect cleaved caspase-9.
DNA synthesis in mammary tumors
The tumors from five animals from each treatment
group were subsequently evaluated for DNA synthesis
rates as inferred by BrdU incorporation. DNA was dena-
tured in situ by incubating unstained paraffin-embedded
tissue sections in 4 N HCl solution for 20 minutes at
37°C. The incorporated BrdU was visualized after expo-
sure to an anti-BrdU mouse monoclonal antibody
(Clone Bu20a; Dako). The numbers of BrdU-positive
S-phase cells per 250 mm
2 were counted in four ran-
dom high power (× 400) fields of viable tissue and the
BrdU labeling index was expressed as number per cm
2.
Blood microvascular density in mammary tumors
Immunohistochemistry based on the LSAB method
(Dako) was performed to quantitatively assess blood
microvessel density in primary mammary carcinomas; a
rabbit polyclonal antibody against CD31 (Lab Vision
Co., Fremont, CA, USA), a marker specific for blood
vessel endothelium, was used. The numbers of CD31-
positive blood microvessels were counted as previously
described [27]; briefly, slides were scanned at low-power
(× 100) magnification to identify those areas having the
highest number of vessels and the five areas of highest
microvascular density were selected and counted at
higher (× 200-400) magnification.
Dilated lymphatic vessels with cancer cell invasion
Mammary tumor sections from paraffin-embedded tis-
sues were immunohistochemically stained using the
LSAB method (Dako). A hamster anti-podoplanin
monoclonal antibody (AngioBio Co., Del Mar, CA,
USA), against a lymphatic endothelium marker was
used. To quantitatively assess the number of lymphatic
vessels having intraluminal tumor cells in the whole per-
iphery area of the primary mammary carcinomas, the
slides were scanned at low-power (x100) magnification
to identify podoplanin-positive lymphatic vessels.
Whether the lymphatic vessel contained mammary can-
cer cells or not was then confirmed at higher (x200-400)
magnification [20].
Statistical analysis
Significant differences in the quantitative data between
groups were analyzed using the Student’s t-test via the
method of Welch, which provides for insufficient homo-
geneity of variance. The differences in metastatic inci-
d e n c ew e r ee x a m i n e db yF i s h e r ’s exact probability test,
with either P <0 . 0 5o rP < 0.01 considered to represent
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analyzed using the Holm-Sidak method.
Results
Cell viability of mammary carcinoma cells treated with a-
mangostin
Viability analyses of BJMC3879luc2 mammary cancer
cells exposed to a-mangostin showed significantly
decreased viability after 24 and 48 hours of treatment
with > 12 μM compound (Figure 2A). Based on the IC50
data, 12 μM was determined to be the optimal concen-
tration of a-mangostin for the in vitro studies.
In vitro a-mangostin-induced apoptosis
Caspase activity
Significantly elevated caspase-3, caspase-8 and caspase-9
activity was observed in BJMC3879luc2 cells treated
with a-mangostin for 24 hours (Figure 2B), compared to
the respective controls. The activity of caspase-12 did
not differ significantly between control cells and a-man-
gostin-treated cells (Figure 2B). Further, BJMC3879luc2
cells treated with 12 μM a-mangostin for 48 hours
showed a greater number of apoptotic cells by TUNEL
staining compared to the control (data not shown).
Release of cytochrome c
The levels of cytochrome c protein in cytosolic fractions
were significantly higher in cells treated with a-mangostin
alone for 24 hours (Figure 2C), strongly suggesting the
engagement of the mitochondria-mediated apoptotic
pathway.
Bid cleavage
Since caspase-8 activities were elevated, we examined
whether the mitochondrial pathway via caspase-8-Bid clea-
vage occurred by performing western blots for Bid. Full-
length Bid (22 kDa) was equally detected in control cells
and in cells treated with a-mangostin only for 24 hour
(Figure 2D). No cleaved Bid (15 kDa) was found in any of
the groups.
Caspase inhibitor experiment
To determine whether caspase activation is necessary
(possibly of caspase-independent apoptosis) to induce a-
mangostin-induced apoptosis, a caspase inhibitor experi-
ment was conducted. Inhibition of caspase activation
through the application of all specific inhibitors resulted in
protection of cell viability in a-mangostin-treated cultures
when compared to cultures treated with a-mangostin
alone (Figure 2E).
Cell cycle of mammary carcinoma cells treated with a-
mangostin
As measured by flow cytometry, 24 hour exposure to 12
μM a-mangostin induced a significant elevation in the
number of cells in the G1-phase compared with control
cells (Figure 2F). There was also a significant reduction
in the S-phase population in the a-mangostin-treated
cell suspensions (Figure 2F).
In vivo survival rates, body weights and mammary tumor
growth
Survival rates are shown in Figure 3A. Although five ani-
mals (50%) in the 0 mg/kg/day group and two animals
(20%) in the 10 mg/kg/day/day group died by week 7 due
to the widespread metastasis of mammary carcinoma, no
mice died in the 20 mg/kg/day group, a statistically sig-
nificant difference (P < 0.05). Body weight changes in
control and a-mangostin-treated mice bearing mammary
tumors are shown in Figure 3B. The weights of control
and a-mangostin-treated mice bearing mammary tumors
did not differ statistically throughout the experiment,
with the exception of the 20 mg/kg/day mice at week 1.
Tumor volumes are presented in Figure 3C. Tumor
growth, as inferred by computed volume, was signifi-
cantly inhibited in the 10 mg/kg/day group from week 1
t o2a n di nt h e2 0m g / k g / d a yg r o u pf r o mw e e k1t o5 ,
compared with controls. By the end of the experiment,
the average tumor volume in control animals was 993 ±
612 mm
3, while the average tumor volume of mice that
received 10 or 20 mg/kg/day a-mangostin was 785 ±
170 mm
3 and 744 ± 292 mm
3, respectively.
Mammary carcinoma metastasis with a-mangostin
treatment
Bioluminescence imaging
Bioluminescence imaging showed signal indicative of
metastatic growth in the mandibular, axillary and ingu-
inal lymphatic regions of all groups; however, there was
a tendency for decreased metastatic expansion in mice
treated with a-mangostin compared to control animals
(Figure 4A). Histopathology of primary mammary
tumors
Histopathologically, the mammary tumors induced by
BJMC3879luc2 cell inoculation proved to be moderately
differentiated adenocarcinomas (Figure 4B) containing
mutated p53 as inferred by immunohistochemistry
(Figure 4C).
Lymph node metastasis
Representative examples of lymph node metastases are
shown in Figures 4D and 4E. Lymph node metastasis
occurred in 100% of mice in the 0 mg/kg/day/day group
and in 90% of the mice in the 10 and 20 mg/kg/day groups.
However, the number of metastasis-positive lymph nodes
per mouse was significantly lower in the 20 mg/kg/day
group compared to the control group (Figure 5A).
Lung metastasis
Lung metastasis also occurred in all mice regardless of
treatment (Figures 4F, G). Although the number of
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Figure 2 Apoptosis and cell cycle in vitro study (mouse mammary carcinoma BJMC3879luc2 cells). (A) Cell viability was significantly lower
in mouse mammary carcinoma BJMC3879luc2 cells treated with more than 12 μM a-mangostin for 24 or 48 hours (**P < 0.01). Five samples
from each dosage of a-mangostin were examined. The IC50 concentration was determined to be 12 μM; therefore, 12 μM a-mangostin and 24
hour-incubation was used for all in vitro studies. (B) Caspase activities were evaluated using the luminescence assay. Activities of caspase-3,
caspase-8 and caspase-9, but not caspase-12, were significantly elevated in BJMC3879luc2 cells treated with 12 μM a-mangostin for 24 hours (*P
< 0.05 or **P < 0.01). Six samples from the control and eight samples from a-mangostin-treated cells were used for measurement of caspase-3
activity, and three samples from each group were used for activity measurements of the other caspases. (C) Cytochrome c in the cytosolic
fraction, as determined by ELISA, was significantly increased in BJMC3879luc2 cells treated with a-mangostin for 24 hours compared to control
levels (*P < 0.05). Three samples each from the control and a-mangostin-treated cell cultures were examined. (D) Western blots of Bid (22 kDa)
in BJMC3879luc2 cells treated with or without a-mangostin for 24 hours were similar (upper panel). Cleaved Bid (15 kDa) was not observed after
a-mangostin treatment. b-Actin served as the internal control (lower panel). (E) In BJMC3879luc2 cells treated with a-mangostin for 24 hours,
cell viability was significantly increased by 10 or 100 μM of the broad-spectrum caspase inhibitor z-VAD-fmk, the caspase-3 specific inhibitor Ac-
DNLD-CHO, the caspase-8 specific inhibitor z-IETD-fmk, and the caspase-9 specific inhibitor z-LETD-fmk (**P < 0.01). (F) Cell-cycle analysis showed
that a-mangostin induced arrest in the G1-phase and inhibition of cells entering the S-phase in metastatic mouse mammary carcinoma
BJMC3879luc2 cells (**P < 0.01). Data are presented as mean ± SD. Ac: acetyl; CHO: aldehyde; ELISA: enzyme-linked immunosorbent assay; fmk:
fluoromethyl ketone; z: N-benzyloxycarbonyl.
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Figure 3 Survival rates, body weights and tumor volumes in mammary carcinomas of mice treated with 0, 10 and 20 mg/kg/day a-
mangostin. a-Mangostin was administered via implanted mini-osmotic pumps. Each group consisted of ten mice. (A) Survival rates (%) were
significantly greater in the 20 mg/kg/day group than the control group (*P < 0.05). (B) Body weights of mice treated with 10 and 20 mg/kg/day
a-mangostin were similar to those in the control group with the exception of the 20 mg/kg/day mice at week one. (C) Increases in tumor
volume in the 20 mg/kg/day group were significantly lower in weeks one to five compared to the control values (*P < 0.05; **P < 0.01). In the
10 mg/kg/day/day group, significant suppression of the tumor volume was observed in weeks one and two, with a decrease in growth
suppression noted thereafter. Data are presented as mean ± SD.
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Figure 4 Bioluminescent imaging and histopathological findings. (A) Bioluminescent imaging in five representative mice from each group
(0, 10 and 20 mg/kg/day groups). Bioluminescent imaging showed that the extension of metastasis tended to be lower in the a-mangostin-
treated groups compared to the control group. (B) The implanted mammary carcinomas proved to be moderately differentiated
adenocarcinoma. Scale bar = 50 μm. (C) p53 immunohistochemistry of mammary carcinomas induced by BJMC3879luc2 cell inoculation. Note
the nuclear staining for abnormal p53 protein, indicating that these cells carry mutant p53. Scale bar = 25 μm. (D) Metastasis to a lymph node
in a control mouse. Scale bar = 250 μm. Metastatic carcinoma cells filled the sinusoidal space (higher magnification in box, inset). (E) A lymph
node from a mouse given 20 mg/kg/day a-mangostin. Scale bar = 250 μm. Metastatic carcinoma cells filled the subcapsular sinus (higher
magnification in box, inset). (F) Metastatic foci in the lung of a control mouse. Many metastatic foci and small to large nodules were seen. Scale
bar = 250 μm. (G) Metastatic foci in the lungs of mice given 20 mg/kg/day a-mangostin. Scale bar = 250 μm. (A): Bioluminescent imaging;( B
and D-G): H&E stain; (C): p53 immunohistochemistry.
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Figure 5 Quantitative analyses of metastasis, apoptosis, DNA synthesis and vascular density in mammary carcinomas. (A) The
multiplicity of lymph node metastasis was significantly lower in the 20 mg/kg/day a-mangostin group (*P < 0.05). (B) The multiplicity of lung
metastasis tended to be lower in the a-mangostin-treated groups, but this was not statistically significant. (C) Apoptotic cell death, assessed by
TUNEL staining, was significantly higher in the 20 mg/kg/day a-mangostin group (*P < 0.05). (D) BrdU labeling indices tended to be lower in
the 20 mg/kg/day a-mangostin group. (E) Microvessel density in tumors, inferred by CD31-positive endothelium, was significantly lower in the
10 and 20 mg/kg/day a-mangostin groups. (F) The number of dilated lymphatic vessels containing intraluminal tumor cells was significantly
lower in the 20 mg/kg/day a-mangostin group than in the control group (*P < 0.05). Data are presented as mean ± SD. BrdU: 5-bromo-2’-
deoxyuridine; TUNEL: terminal deoxynucleotidyl transferase-mediated dUTP-FITC nick end-labeling.
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Page 10 of 18metastatic lung foci > 1 mm in diameter per mouse
tended to be lower in the a-mangostin-treated groups,
this decrease was not statistically significant (Figure 5B).
In vivo apoptosis and DNA synthesis in mammary tumors
of a-mangostin-treated mice
Representative examples of TUNEL-positive cells from
mammary tumor tissues are presented in Figures 6A
and 6B. The results of the quantitative analysis for apop-
tosis in mammary tumors, as assessed by the TUNEL
assay, are shown in Figure 5C. The number of TUNEL-
positive cells was significantly higher in tumors from the
20 mg/kg/day groups as compared to the numbers in
tumors from the control mice (Figure 5C). Immunohis-
tochemistry demonstrated much higher expression of
the active forms of caspase-3 and caspase-9 in mam-
mary tumors of mice treated with a-mangostin (Figures
6D, F) when compared to those of the control animals
(Figures 6C, Figure 6E), suggesting that a-mangostin
induces mitochondria-mediated apoptosis in mammary
tumor cells in vivo as well as in vitro.
DNA synthesis levels in mammary carcinomas of a-
mangostin-treated mice, as inferred by BrdU labeling
indices, are shown in Figure 5D. The level of DNA
synthesis in tumors tended to be lower in the 20 mg/kg/
day group, but this decrease was not statistically signifi-
cant (Figure 5D).
Effect of a-mangostin on microvascular density and
cancer cell migration via lymphatic vessels
Microvessel density, as determined by immunohisto-
chemical analysis with the blood vessel endothelial cell
marker CD31 (Figures 6G, H), was significantly lower in
the 10 and 20 mg/kg/day a-mangostin groups compared
to the 0 mg/kg/day group (Figure 5E).
The lymphatic vessels in mammary tumors were
stained with anti-podoplanin antibody, as demonstrated
in Figures 6I and 6J, to detect malignant cell migration.
Tumor cells were found within the lumina of dilated
lymphatic vessels of tumors in both the control (Figure
6I) and a-mangostin-treated (Figure 6J) animals; how-
ever, the number of dilated lymphatic vessels containing
intraluminal tumor cells (arrows in Figures 6I, J) was
significantly lower in mammary tumors of mice given
20 mg/kg/day of a-mangostin (Figure 5F), indicating a
reduction in the number of tumor cells migrating into
the lymphatic vessels of tumor tissues.
Effects of a-mangostin on Akt phosphorylation
In vitro
As shown in Figure 7A, the levels of total Akt in a-
mangostin-treated cells had transiently decreased at
3 hours, but had recovered by 6 hours. Although the
levels of phospho-Akt-Thr308 in a-mangostin-treated
cells were significantly lower at 3 hours and 6 hours, the
levels of phospho-Akt-Ser473 were unchanged but with
large variations at 3 hours. Western blots revealed that,
although there were no apparent differences in total Akt
levels between control and a-mangostin-treated mam-
mary carcinoma cells, phospho-Akt-Thr308 was lower
in mammary carcinoma cells treated with a-mangostin
for 24 hours (Figure 7B). There were wide variations
among mice, but, overall, phospho-Akt-Ser473 tended
to marginally decrease with a-mangostin treatment
(Figure 7B).
In vivo
Compared to expression of phospho-Akt-Thr308 in
control mammary carcinomas (Figure 8A), the number
of positive cells and their staining intensity was mark-
edly lower in mammary carcinomas of mice treated with
20 mg/kg/day a-mangostin (Figure 8B). As shown under
higher magnification, strong nuclear expression with
weaker cytoplasmic expression of phospho-Akt-Thr308
was observed in mammary carcinoma cells in the con-
trol (Figure 8C) and 20 mg/kg/day groups (Figure 8D).
However, the levels of phospho-Akt-Thr308 were much
lower in the 20 mg/kg/day group than in the control
group. There was no apparent difference between phos-
pho-Akt-Ser473 expression between the control and
a-mangostin 20 mg/kg/day groups (data not shown).
Discussion
The present study showed that treatment with 20 mg/kg/
day a-mangostin resulted in prolonged survival rates and
increased inhibition of tumor growth and lymph node
metastasis in an immunocompetent mouse metastatic
mammary carcinoma model containing a p53 mutation.
Mammary carcinoma tissues of mice treated with 20 mg/
kg/day a-mangostin showed elevation of apoptotic cell
death, increased expression of active caspase-3 and -9,
and a decrease in the number of cells with phospho-Akt-
Thr308. Furthermore, decreased blood microvessel den-
sity and fewer numbers of lymphatic vessels containing
intraluminal cancer cells were observed in mammary car-
cinomas of a-mangostin-treated mice. Our in vitro stu-
dies have demonstrated that a-mangostin induces
mitochondria-mediated apoptosis, but not via the Bid-
mitochondria cross-talk pathway, G1-phase arrest, or
S-phase suppression in the cell cycle.
Akt phosphorylation contributes to cell proliferation,
anti-apoptotic cell death, cell cycle entry, angiogenesis
and metastasis - all important aspects of the oncogenic
process [28]. The phosphoinositide 3-kinase (PI3K)/Akt
pathway is now considered to be an important therapeu-
tic target for cancer. Indeed, Akt inhibitors have shown
significant promise preclinically and are now in clinical
trials [29]. Full activation of Akt is a multistep process,
and the final step is phosphorylation of Akt1 at two
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Figure 6 Apoptosis, active-caspase expression, angiogenesis and dilated lymphatic vessels with cancer cell invasion in mammary
carcinomas. TUNEL-positive apoptotic cells are much more frequently seen in the tumor of a mouse given 20 mg/kg/day a-mangostin (B) than
in the tumor of a control mouse (A). Expression of active caspase-3 (C, D) and active caspase-9 (E, F) was more prominent in the tumor of a
mouse given 20 mg/kg/day a-mangostin (D, F) than in a control mouse (C, E). The number of CD-31-positive endothelial cells was lower in the
tumor of a mouse given 20 mg/kg/day a-mangostin (H) compared to that of a control mouse (G). Podoplanin-positive lymphatic vessels of a
tumor in a control mouse were often dilated and filled with tumor cells (arrow, I). Mammary cancer cells were also observed in the intraluminal
space of the dilated lymphatic vessels in the tumor of a mouse given 20 mg/kg/day a-mangostin (arrow, J). (A-H): Scale bar = 50 μm; (I, J):
Scale bar = 25 μm. (A, B): TUNEL stain; (C, D): active caspase-3 immunohistochemistry; (E, F): active caspase-9 immunohistochemistry; (G, H): CD31
immunohistochemistry; (I, J): podoplanin immunohistochemistry.
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Figure 7 Akt phosphorylation in vitro. Akt phosphorylation plays a central role in a variety of oncogenic processes. (A) Quantitative analysis of
phospho-Akt in MDA-MB231 cells treated with 20 μM a-mangostin showed that although total Akt showed a transient decease at 3 hour, the
levels returned to the control levels. The levels of phospho-Akt-Thr308 were significantly lower at 3 hour and 6 hour, but this was not seen for
phospho-Akt-Ser473, which showed large variations. (B) Western blotting showed that there were no apparent differences between control and
a-mangostin-treated cells in total Akt; however, phospho-Akt-Thr308 levels tended to be lower in a-mangostin-treated cells. Phospho-Akt-Ser473
showed a tendency to be slightly lower in a-mangostin-treated cells in western blotting. Ser473: serine 473; Thr308: threonine 308.
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Page 13 of 18sites, Thr308 and Ser473 [30]. Upon activation, Akt
moves to the cytoplasm and nucleus where it phosphor-
ylates downstream target proteins. We demonstrated
that treatment with a-mangostin decreased phospho-
Akt-Th308. In this study, although intense staining of
phospho-Akt-Th308 in both the cytoplasm and nucleus
was immunohistochemically observed in mammary car-
cinoma tissues of the control group, the intensity and
number of cells expressing phospho-Akt-Th308 tended
to be lower in the 20 mg/kg/day a-mangostin group.
Since both Thr308 and Ser473 are necessary for full
activation of Akt [30,31], the fact that a-mangostin
reduced phospho-Akt-Th308 in vitro and in vivo sug-
gests downstream inhibition of pathways in Akt. Several
modes of Akt pathway dysregulation have been identi-
fied in various types of cancer, including breast cancer,
and this ultimately affects a number of processes includ-
ing cell growth, survival, proliferation, and motility and/
or invasion [28]. Therefore, the observation in the
present study of reduced tumor growth, apoptotic cell
death, cell-cycle alterations, anti-angiogenesis and anti-
metastasis may be partially responsible for inhibition of
Akt phosphorylation.
As previously stated, we demonstrated a significant
induction of apoptosis with a-mangostin in murine
mammary carcinoma cells both in vitro and in vivo.
There are two pathways currently proposed to play
major roles in regulating apoptosis in mammalian cells:
a pathway mediated by the death receptor (an extrinsic
pathway, executed by caspase-8), and a pathway
mediated by mitochondria (intrinsic pathway with
execution by caspase-9) [32]. In addition, however,
endoplasmic reticulum (ER) stress has been shown to
switch the signaling direction from the pro-survival to
the pro-apoptotic pathway [33]. Caspase-12, a caspase
localized in the ER, is known to mediate this switch in
mice [34]. Caspase-3 is the final executor of apoptosis.
Many of the apoptotic signals are transduced to the
C  D 
A  B 
Figure 8 Akt phosphorylation in vivo. Akt phosphorylation plays a central role in a variety of oncogenic processes. Compared to the number
of cells positive for phospho-Akt-Thr308 in the mammary carcinoma tissue of a control mouse (A), the number of phospho-Akt-Thr308-positive
cells was markedly lower in the mammary carcinoma tissue of a mouse treated with 20 mg/kg/day a-mangostin (B). Note that stronger nuclear
and weaker cytoplasmic staining was observed in both a control mouse carcinoma (C, higher magnification of the box in A) and a 20 mg/kg/
day a-mangostin-treated mouse carcinoma (D, higher magnification of a box in B). The numbers and intensities of stained cells were weaker in
the 20 mg/kg/day group (B, D) than in the control group (A, C). (A, B): Scale bar = 100 μm; (C, D): Scale bar = 25 μm. (A-D): Phospho-Akt-
Thr308 immunohistochemistry.
Shibata et al. BMC Medicine 2011, 9:69
http://www.biomedcentral.com/1741-7015/9/69
Page 14 of 18mitochondria, decreasing the mitochondrial membrane
potential and leading to the release of cytochrome c
from the mitochondrial lumen into the cytoplasm. The
released cytochrome c binds to the apoptosis protease-
activating factor-1 (Apaf-1), and this complex activates
caspase-9. Caspase-8 also has a cross-talk pathway to
the mitochondrial pathway through the cleavage of Bid
[32].
In vitro, we noted increased activity of caspases-3, -8
and -9 and increased cytosolic cytochrome c levels in a-
mangostin-treated mammary carcinoma cells, suggesting
that a-mangostin at least initiated mitochondria-
mediated apoptosis. In fact, mammary carcinoma tissues
of a-mangostin-treated mice showed strong expression
of active caspase-3 and -9, demonstrating that mito-
chondria-mediated apoptosis actually occurred in vivo as
well. All caspase inhibitors, including that for caspase-8,
completely rescued a-mangostin-induced cell death in
cultures. Bid cleavage, however, was not observed, indi-
cating that cross-talk between caspase-8 and Bid may
not be involved here. The question arises as to why cas-
pase-8 activity nevertheless increased. Caspase-8 partici-
pates in ERK activation, and this participation is
attributed to the Death Effector Domains (DED) of cas-
pase-8 [35] and a direct association between ERK and a
DED-containing fragment of caspase-8, with co-trans-
port of an ERK-caspase-8-DED complex to the nucleus
during apoptosis, has been reported [36]. The caspase-8-
E R Kp a t h w a ym a ya l s op l a yar o l ei na-mangostin-
induced apoptosis, but further investigation is required
to elucidate this mechanism. Since no elevation in cas-
pase-12 activity was seen in the present study, a-man-
gostin-induced apoptosis may not have involved ER
stress. Our current experiments suggest that a-mangos-
tin-induced apoptosis in BJMC3879luc2 cells, which
contain a p53 mutation, occurs through a p53-indepen-
dent mechanism.
The tumor suppressor gene p53 encodes a transcrip-
tion factor that plays a critical role in regulating cell
cycle progression, DNA repair, and cell death. p53 is the
most frequently altered gene in human cancers and loss
of functional p53 protein occurs in a majority of epithe-
lial ovarian cancers. The present experiments suggest
that a-mangostin-induced apoptosis in BJMC3879luc2
cells having a p53 mutation occurs through a p53-inde-
pendent mechanism. Since 50% of human cancers have
p53 mutations [37], the fact that the a-mangostin
induces a p53-independent apoptotic response in cancer
cells having a p53 mutation may be highly relevant to
inhibiting many human cancers. In the case of non-
functional p53 status, p73, the p53 homologue, may play
a role in apoptosis induction. On a related note, it has
been shown that stroma-specific loss of heterozygosity
or allelic imbalance is associated with p53 mutations
and regional lymph-node metastases in sporadic breast
cancer [38].
Neovascularization is a key process in the growth of
solid tumors, and tumors will not grow beyond a few
cubic millimeters unless a vascular network is estab-
lished to feed further expansion [39]. In the present
study, we demonstrated that treatment with a-mangos-
tin significantly reduced microvessel density in mam-
mary carcinomas. We have also recently shown that
panaxanthone, which is comprised of approximately
75% to 85% a-mangostin and 5% to 15% g-mangostin
with the sum of both contents > 90%, also inhibits
tumor growth and metastasis in mouse mammary carci-
nomas and is also associated with decreased tumor
angiogenesis. Since the growth of both primary tumors
and of metastases is angiogenesis-dependent, and since
microvascular endothelial cells recruited by a tumor in
the process of neovascularization have become an
important second target of cancer therapy [40], the anti-
angiogenic properties of a-mangostin may be very
important to the development of cancer therapies, parti-
cularly those involved with molecular targeting in
neoplasms.
Tumor cell dissemination is mediated by a number of
mechanisms, including direct invasion into local tissue,
lymphatic spread, and hematogenous spread. In general,
the most common pathway of initial dissemination is via
the lymphatics, with patterns of spread via afferent ducts
[41]. The lymphatic capillaries present in tissues and
tumors provide entrance into the lymphatic system,
allowing cancer cell migration to the lymph nodes.
Breast cancer cells are known to disseminate through
the body by all of the above mechanisms; common
metastatic sites are the lymph nodes, lung, bones, and
liver [5]. Lymph node involvement remains specifically
the most influential prognostic factor in breast cancer
progression [42]. In the present study, the multiplicity of
lymph node metastases was decreased in a-mangostin-
treated mice. This phenomenon was supported by a sig-
nificant decrease in the number of lymphatic vessels
demonstrating intraluminal tumor cells in the a-man-
gostin-treated groups. This indicates that a-mangostin
has an inhibitory effect on migration into lymphatic ves-
sels. Other investigators have reported that a-mangostin
exerts inhibitory effects on cell invasion and migration
in mammary cancer cells due to downregulation of
MMP-2 and MMP-9 [12], and we cannot preclude that
this mechanism was not operating in our study, as well.
Significant elevations of NK activity were recently
reported in mice treated with crude a-mangostin at 20
and 40 mg/kg/day compared to control mice [25]. In a
human pilot study, healthy people orally administered
panaxanthone, a less purified a-mangostin analog, at a
dose of 150 mg/day/person for seven days also showed
Shibata et al. BMC Medicine 2011, 9:69
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mary cancer model used in the current study was an
immunocompetent model, elevation in NK activity
would be expected in the 20 mg/kg/day a-mangostin
group.
The PI3K pathway exerts its regulatory functions on
cell proliferation, cell transformation, cell apoptosis,
tumor growth and angiogenesis through downstream
targeting of Akt [43]. Expression of Akt in a dominant/
negative mutant also inhibited angiogenesis and tumor
growth, and also decreased the expression of HIF-1a
and vascular endothelial growth factor (VEGF) in tumor
xenographs [44]. Akt has also been reported to phos-
phorylate and activate endothelial nitric oxide synthase
(eNOS), which contributes to angiogenesis through
endothelial nitric oxide production. Activation of Akt by
VEGF orchestrates several signaling events that contri-
bute to angiogenesis [45]. Involvement of PI3K, Akt and
eNOS in endothelial cell biology is apparent under both
physiological and pathological conditions. Akt1 null
mice show reduction of lymphatic capillary vessel size as
well as defects of smooth muscle cell coverage and valve
development, suggesting that Akt1 is a required isoform
in lymphangiogenesis [46]. Thus, Akt-mediated signaling
plays an important role in lymphangiogeneis as well as
in angiogenesis. Since a-mangostin reduced Akt phos-
phorylation in vitro and in vivo in the present study,
this signaling may be responsible for reduction of vascu-
logenesis in our mouse tumors.
Studies have also shown that a-mangostin decreases
the levels of cyclooxygenase-2 (COX-2) and inducible
nitric oxide synthase in macrophages [47]. COX is a key
enzyme that catalyzes the conversion of arachidonic acid
to prostaglandin E2 (PGE2). Recent studies have shown
that overexpression of COX-2 and PGE2 is a characteris-
tic of many human cancers [48-50] and selective COX-2
inhibitors have shown significant effects in reducing the
incidence and progression of tumors and metastasis in
animal models of mammary cancer [51-53]. Therefore,
the observed antitumor action by a-mangostin in our
present study may be due to reduction of COX-2 levels.
Akt signaling has been reported to upregulate COX-2
expression through the NF-kB/IkB pathway in mutated
PTEN endometrial carcinoma cells [54]; a-mangostin
m a yb ea b l et or e d u c eC O X - 2e x p r e s s i o nt h r o u g hA k t
dephosphorylation.
Estrogen and the estrogen receptor a (ERa)a r ew i d e l y
recognized to play a crucial role in the development and
progression of hormone-dependent breast cancer. The
BJMC3879luc2 mammary carcinoma cells used in the pre-
sent study have been previously characterized as having
cytoplasmic location of ERa and a partial weak response
to estrogen treatment [17]. When BJMC3879luc2 cells are
implanted into mice, ERa mRNA levels rise significantly
higher in females than males. Raloxifene, a selective estro-
gen receptor modulator, inhibits tumor growth and metas-
tasis in the same mouse metastatic mammary carcinoma
model as we used in the present study [17]. Aromatase is
an estrogen synthase responsible for catalyzing the bio-
synthesis of estrogens from androgens. Since both a- and
g-mangostin inhibit aromatase activity in a dose-depen-
dent manner, this is another possible mechanism by which
a-mangostin exhibited the antitumor effect seen in the
present study.
The population is aging in many modern societies,
and since the morbidity rates of cancer and cerebrovas-
cular disease are increasing steadily, preventive medi-
cine, in addition to therapeutic treatments, is becoming
increasingly important. Many medically advanced socie-
ties are exploring both Western medicine and Oriental
alternatives, and the demand for complementary and
alternative medicines is on the rise. In fact, the 2007
National Health Interview Survey by the National Cen-
ter for Complementary and Alternative Medicine
(NCCAM) and the National Center for Health Statistics
showed that 38% of adults in the United States are
using some form of complementary and alternative
medicine [55]. However, scientific data based on the
principle of evidence-based an a l y s i si ss t i l ls c a n ti nt h e
fields of complementary and alternative medicine. a-
Mangostin, isolated from the pericarp of the mangos-
teen fruit, has been shown to induce many biological
actions, such as anti-bacterial activity [56], apoptosis
[7-10], and cell-cycle arrest [7]. An analog, panax-
anthone (approximately 75% to 85% a-mangostin and
5% to 15% g-mangostin with the sum of both contents >
90%) has been shown to significantly suppress tumor
growth and metastasis in a mouse model of mammary
cancer when administered in the diet [14]. These and
other basic investigations provide a scientific basis for
the anecdotal effects of a-mangostin.
Conclusions
We have demonstrated that treatment with a-mangostin
induces a significant increase in survival and suppression
of tumor growth and lymph node metastasis in a mouse
mammary cancer model carrying a p53 mutation. Given
that lymph node involvement is the most important prog-
nostic factor in breast cancer patients, the antimetastatic
activity of a-mangostin, in particular, may be a crucial
finding with future clinical application. In addition, a-
mangostin may be useful as an adjuvant therapy or com-
plementary alternative medicine and, possibly, as a tool for
the chemoprevention of breast cancer development.
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